Analyst Price Targets — ACLX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 25, 2026 11:35 pm | — | Guggenheim | $115.00 | $113.76 | TheFly | Arcellx downgraded to Neutral from Buy at Guggenheim |
| February 24, 2026 5:39 am | Michael Yee | UBS | $115.00 | $113.75 | StreetInsider | UBS Downgrades Arcellx Inc. (ACLX) to Neutral |
| February 24, 2026 1:12 am | Market Perform | Leerink Partners | $115.00 | $113.75 | TheFly | Arcellx downgraded to Market Perform from Outperform at Leerink |
| February 23, 2026 11:17 pm | — | Stifel Nicolaus | $115.00 | $113.75 | TheFly | Arcellx downgraded to Hold from Buy at Stifel |
| February 23, 2026 6:23 pm | Cory Kasimov | Evercore ISI | $115.00 | $113.81 | TheFly | Arcellx downgraded to In Line from Outperform at Evercore ISI |
| February 23, 2026 4:19 pm | Emily Bodnar | H.C. Wainwright | $115.00 | $113.82 | TheFly | Arcellx downgraded to Neutral from Buy at H.C. Wainwright |
| February 23, 2026 1:58 pm | — | Canaccord Genuity | $115.00 | $113.91 | TheFly | Arcellx downgraded to Hold from Buy at Canaccord |
| February 23, 2026 1:41 pm | — | Wells Fargo | $115.00 | $114.09 | TheFly | Arcellx downgraded to Equal Weight from Overweight at Wells Fargo |
| February 23, 2026 1:35 pm | — | Robert W. Baird | $115.00 | $114.10 | TheFly | Arcellx downgraded to Neutral from Outperform at Baird |
| February 23, 2026 1:24 pm | — | Truist Financial | $120.00 | $114.10 | TheFly | Arcellx downgraded to Hold from Buy at Truist |
Latest News for ACLX
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that all required regulatory approvals have been obtained for its previously announced acquisition of Arcellx and that Gilead has extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx. On April 13, 2026, the Australian Competition and Consumer Commission (ACCC) published its…
Banque Pictet and Cie SA bought a new stake in shares of Arcellx, Inc. (NASDAQ: ACLX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 5,109 shares of the company's stock, valued at approximately $333,000. Several other large investors also recently modified
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx. The offer remains at a purchase price of (1) $115.00 per share, net to the seller in cash, without interest, subject to any withholding tax, plus (2) one contractual contingent value right (CVR), which represents the right to…
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Kennedy-Wilson Holdings, Inc. (NYSE: KW)'s sale to consortium led by William McMorrow, Chairman and Chief Executive Officer of Kennedy-Wilson, and certain other…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ACLX.
U.S. House Trading
No House trades found for ACLX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.